Merck has decided to stop selling its niacin-containing drug, Tredaptive, in the markets where was approved. The drug was never approved in the U.S. Here is a letter Merck earlier sent to doctors to let them know that a clinical trial found Tredaptive did not prevent heart attacks and other cardiovascular problems but that it did cause serious side effects.
Merck has decided to stop selling its niacin-containing drug, Tredaptive, in the markets where was approved. The drug was never approved in the U.S. Here is a letter Merck earlier sent to doctors to let them know that a clinical trial found Tredaptive did not prevent heart attacks and other cardiovascular problems but that it did cause serious side effects.
Merck has decided to stop selling its niacin-containing drug, Tredaptive, in the markets where was approved. The drug was never approved in the U.S. Here is a letter Merck earlier sent to doctors to let them know that a clinical trial found Tredaptive did not prevent heart attacks and other cardiovascular problems but that it did cause serious side effects.